- Home
- GRF vs ATNM Comparison
GRF vs ATNM Comparison
Compare GRF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- ATNM
- Stock Information
- Founded
- GRF 1989
- ATNM 2000
- Country
- GRF United States
- ATNM United States
- Employees
- GRF N/A
- ATNM N/A
- Industry
- GRF Finance/Investors Services
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- GRF Finance
- ATNM Health Care
- Exchange
- GRF Nasdaq
- ATNM Nasdaq
- Market Cap
- GRF 42.6M
- ATNM 50.2M
- IPO Year
- GRF N/A
- ATNM N/A
- Fundamental
- Price
- GRF $10.62
- ATNM $1.58
- Analyst Decision
- GRF
- ATNM Strong Buy
- Analyst Count
- GRF 0
- ATNM 2
- Target Price
- GRF N/A
- ATNM $4.50
- AVG Volume (30 Days)
- GRF 3.0K
- ATNM 116.8K
- Earning Date
- GRF 01-01-0001
- ATNM 11-13-2025
- Dividend Yield
- GRF 3.70%
- ATNM N/A
- EPS Growth
- GRF N/A
- ATNM N/A
- EPS
- GRF 1.16
- ATNM N/A
- Revenue
- GRF N/A
- ATNM N/A
- Revenue This Year
- GRF N/A
- ATNM N/A
- Revenue Next Year
- GRF N/A
- ATNM N/A
- P/E Ratio
- GRF $8.15
- ATNM N/A
- Revenue Growth
- GRF N/A
- ATNM N/A
- 52 Week Low
- GRF $7.93
- ATNM $1.03
- 52 Week High
- GRF $10.19
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- GRF 54.48
- ATNM 42.17
- Support Level
- GRF $10.51
- ATNM $1.56
- Resistance Level
- GRF $10.72
- ATNM $1.64
- Average True Range (ATR)
- GRF 0.14
- ATNM 0.06
- MACD
- GRF -0.02
- ATNM -0.01
- Stochastic Oscillator
- GRF 36.38
- ATNM 6.67
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.